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Caveolin proteins drive formation of caveolae, specialized cell-surface microdomains that influence cell
signaling. Signaling proteins are proposed to use conserved caveolin-binding motifs (CBMs) to associate
with caveolae via the caveolin scaffolding domain (CSD). However, structural and bioinformatic analyses
argue against such direct physical interactions: in the majority of signaling proteins, the CBM is buried
and inaccessible. Putative CBMs do not form a common structure for caveolin recognition, are not enriched
among caveolin-binding proteins, and are even more common in yeast, which lack caveolae. We propose
that CBM/CSD-dependent interactions are unlikely to mediate caveolar signaling, and the basis for signaling
effects should therefore be reassessed.Introduction
The caveolin signaling hypothesis is an enduring model for
understanding spatial organization of signaling at the plasma
membrane (Couet et al., 1997; Lisanti et al., 1995; Okamoto
et al., 1998). The central tenet of the model is that signaling
proteins can form direct protein-protein interactions with the
scaffolding domain of caveolin (CSD) via a signature peptide
sequence, termed the caveolin binding motif (CBM) (Couet
et al., 1997; Oka et al., 1997) (Figure 1). The characteristic
CBMs were originally identified by the screening of a phage
display peptide library (Couet et al., 1997) and were subse-
quently found to be present in many diverse proteins that could
be immunopurified with caveolin. These consensus CBMs
are hydrophobic and rich in aromatic residues (UxUxxxxU or
UxxxxUxxU or the combined sequence UxUxxxxUxxU, where
U is a Phe, Tyr, or Trp residue and x can be any amino acid)
(Table 1; see also Figure S1 available online). The caveolin inter-
action is generally suggested to have an inhibitory role on
signaling. Thus, signaling proteins associated with the cyto-
plasmic face of caveolae were proposed to be held in an inactive
state by the caveolin ‘‘brake,’’ prior to release from caveolae
upon activation (Okamoto et al., 1998).
Numerous signaling proteins have been proposed to interact
with caveolin, including cytoplasmic proteins (src family kinases,
trimeric G protein subunits, Ras, PPARg, b-catenin), and single
and multispan transmembrane proteins (Patched, b-adrenergic
receptors [b-ARs], adiponectin receptors) (Burgermeister et al.,
2011; Couet et al., 1997; Hezel et al., 2010; Ju et al., 1997;
Karpen et al., 2001; Li et al., 1996; Michel et al., 1997; Mineo
et al., 1997, 1998; Song et al., 1996, 1997; Toya et al., 1998;
Venema et al., 1997) (Table 1; Figure S1). The hypothesis has
been extended to caveolin interactions with nonsignaling
proteins, including extracellular viral proteins (Benferhat et al.,2008, 2009a, 2009b; Hovanessian et al., 2004) and key autopha-
gic regulators such as LC3 (Chen et al., 2010), and has become
a paradigm for spatial regulation of signaling pathways.
Despite the elegance of the model and the wealth of literature
supporting it, including indirect experimental data showing asso-
ciation of specific proteins with caveolin or inhibition by CSD
mimetic peptides (e.g., Bucci et al., 2000), some questions
have been raised (Liu et al., 2002; Pike, 2005), and a number of
crucial aspects of the model have never been systematically or
rigorously addressed. For example, do the putative CBMs adopt
a common structure, as would be predicted by the model? Are
CBMs accessible for interaction with caveolin and positioned
in such a way with respect to the caveolin-containing membrane
that an interaction is feasible? How common are such motifs,
and are they enriched in caveolae-associated proteins? Surpris-
ingly, a plausible molecular mechanism for the interaction of
CBMs with caveolin is yet to emerge. The wealth of genomic
sequence and tertiary structural information available on
putative caveolin-interacting proteins now means that these
questions can be definitively answered. As outlined below, the
answers to these questions raise major doubts about some of
the founding principles on which the caveolar signaling model
is based, leading us to propose that a significant reassessment
of the caveolin signaling hypothesis may be needed.
Structures of Putative Caveolin Binding Proteins Do Not
Reveal a Plausible Caveolin Binding Mechanism
The putative CBM is a short, hydrophobic sequence of 8–11
amino acid residues (Table 1; Figure S1). Two physical require-
mentsmust bemet if it is to function as a bona fide caveolin inter-
action motif. The first requirement is that a functional CBM either
must lie in a disordered region of the interacting protein
(becoming ordered upon caveolin interaction) or must formDevelopmental Cell 23, July 17, 2012 ª2012 Elsevier Inc. 11
Figure 1. The Caveolin Signaling
Hypothesis
(A) Schematic of the caveolin signaling hypothesis
as originally proposed (Okamoto et al., 1998), with
some key interacting partners highlighted. The
sequence of the caveolin-1 scaffolding domain
(CSD) and the consensus caveolin-binding motif
(CBM) are shown.
(B andC) Twomodels for caveolin association with
the membrane bilayer. In model (B), the CSD is
exposed and shown in an extended conformation,
allowing interactions with signaling proteins.
However, note that the middle of the CSD is still
very close to the membrane, even assuming
a completely extended polypeptide conformation
perpendicular to the bilayer. Model (C), in which
the CSD forms part of an amphipathic cholesterol-
binding in-plane helix, is an alternative model
supported by a number of studies (Kirkham et al.,
2008).
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second requirement for a role of caveolin in sequestering
proteins into caveolae is that the putative CBM should be
exposed in the folded protein structure and accessible to the
CSD.
We analyzed the structures of more than 40 proteins for which
caveolin interactions with specific CBMs have been described
(Table 1; Figure S2). Some specific examples are shown in
greater detail in Figure 2 and Movie S1. This clearly reveals
that no single common structural motif is adopted by the putative
caveolin-interacting sequences. The CBM adopts a variety of
different structures within the putative caveolin binding proteins,
including extended structures, a helices, b strands, and b turns,
and no consistent conformation for this peptide is observed.
Even within individual protein families, including tyrosine
kinases, G-protein coupled receptor (GPCRs), and protein tyro-
sine phosphatases, the motif adopts diverse structural orienta-
tions. For example, in the epidermal growth factor receptor
(EGFR) and protein kinase C (PKC) kinase domains, the putative
CBMs are found in distinct substructures, forming either a central
a helix within the C-terminal lobe or a peripheral b strand on the
edge of the N-terminal lobe, respectively (Figure 2). The other
major observation is that these motifs are invariably found within
structured regions of the proteins, often forming essential
secondary structure elements. This is in distinct contrast, for
example, with the recognition of multiple sorting signals and
sequence motifs during formation of the analogous clathrin-
coated vesicle (CCV) assembly (Owen et al., 2004; Traub,
2009). In CCVs, peptide interaction motifs are always found in
structurally disordered domains and only adopt an ordered
conformation upon interaction with folded domains within their
partner molecule(s).
The second crucial requirement of the model, the accessibility
of the CBM to interacting proteins, is also illuminated by exami-
nation of the 3D structures. As discussed above, no common12 Developmental Cell 23, July 17, 2012 ª2012 Elsevier Inc.structural motif is observed for the
numerous putative CBM sequences.
Even more tellingly, in the large majority
of cases these sequences are completely
inaccessible for interaction with caveolin.Figure 2 shows several different examples in which the CBM is
not only inaccessible but also forms an essential part of the
protein tertiary structure. Table 1 examines the solvent accessi-
bility of putative CBMs based on the known crystal structures.
The CBM sequence is hydrophobic and rich in aromatic side
chains, and we find that in all cases the aromatic side chains
are packed within the hydrophobic core of the putative caveolin
binding proteins. By focusing on just one of these, endothelial
nitric oxide synthase (eNOS), for which there are numerous
reports of caveolin scaffolding domain interactions (Bernatchez
et al., 2011; Bucci et al., 2000; Feron et al., 1998; Garcı´a-
Carden˜a et al., 1997; Hatakeyama et al., 2006; Levin et al.,
2007; Zhu et al., 2004), we find that themotif forms a key b strand
element within the hydrophobic interior of the protein. The
aromatic side chains are tightly packed in the protein core and,
even more strikingly, directly contact the critical heme group
within the protein’s active site (Figure 2). It is extremely unlikely
that this sequence could bind to caveolin without dramatic and
detrimental conformational changes occurring. Similar observa-
tions can be made for the majority of other proteins for which
structural data is available.
Could Conformational Changes Facilitate Caveolin
Binding?
One possibility we considered was that the CBMs could become
accessible upon conformational changes in the target proteins.
This also appears unlikely in view of the critical structural roles
of the majority of these peptides. Invoking the hypothesis that
a conformational change could lead to binding may be a reason-
able explanation, perhaps, for a single or small number of
binding events (although notably there is currently no data to
support such a model). However, given the large range of
different proteins from diverse structural and functional classes
we have examined here, conformational change in the signaling
molecules appears highly implausible as a universal explanation.
Table 1. Putative Caveolin Binding Motifs (CBMs) Identified in Previous Studiesa
Protein Proposed CBM(s) Referenceb
Protein for
Structural
Analysis
PDB
ID
Structure
Reference
Secondary
Structure
Accessible
Surface
Area (%)c
Consensus CBM UxUxxxxUxxU (Couet et al., 1997)     
Soluble Proteins
b-catenin YTYEKLLW (Mo et al., 2010)* b-catenin 2Z6G (Xing et al., 2008) a helix 36
ApoE WELALGRFWDYLRW31 (Yue and Mazzone, 2011) ApoE 1YA9 (Hatters et al., 2005) a helix 32
BTK WAFGVLMWEIY591 (Vargas et al., 2002) BTK 1K2P (Mao et al., 2001) a helix 1
Dystrophin FHYDIKIFNQW (Couet et al., 1997) none    
eNOS FPAAPFSGW356 (Couet et al., 1997;
Garcı´a-Carden˜a et al.,
1997; Sato et al., 2004)*
eNOS 1M9K (Rosenfeld et al., 2002) b strand 11
Ga subunits FTFKDLHFKMF199 (Couet et al., 1997;
Li et al., 1995)
Gai1 1CIP (Coleman and Sprang,
1999)
b hairpin 32
Gaq 3AH8 (Nishimura et al., 2010) b hairpin 44
GFPd FAYGVQCFSRY this study GFP 3OGO (Kubala et al., 2010) extended
coil

Heme oxygenase-1 FLLNIELF214 (Taira et al., 2011) heme
oxygenase-1
1DVE (Sugishima et al., 2000) a helix 18
LC3B FLYMVYASQETF119 (Chen et al., 2010) LC3B 2ZJD (Ichimura et al., 2008) b strand 13
MAP kinase YIVGFYGAF133 (Couet et al., 1997) MEK1 3PP1 (Dong et al., 2011) b strand 21
Myosin HC WPWMKLYF836 (Couet et al., 1997) myosin HC 2MYS (Rayment et al., 1993) a helix 51
NSF FSFNEKLF145 (Couet et al., 1997) NSF 1QCS (Yu et al., 1999) b hairpin 38
Nuclear erythroid 2
p45-related factor2
FGDEFYSAF289 (Li et al., 2012)     
PKCa FSYVNPQF663 (Oka et al., 1997) PKCa 3IW4 (Wagner et al., 2009) b strand 32
PPARge FGDFMEPKFEF370 (Burgermeister
et al., 2011)*
PPARg 3ETO (Artis et al., 2009) a helix 23
PTEN FHFWVNTF278 (Caselli et al., 2002;
Xia et al., 2010)*
PTEN 1D5R (Lee et al., 1999) b strand 7
PTP1B FHYTTWPDF182 (Caselli et al., 2002) PTP1B 2CM2 (Ala et al., 2006) b strand 28
PTP1C (SHP-1) FVYLRQPY213 (Caselli et al., 2002) SHP-1 3PS5 (Wang et al., 2011) b strand 32
SH-PTP2 WQYHFRYW423 (Caselli et al., 2002) SH-PTP2 3B7O (Barr et al., 2009) b strand 15
Src family kinases WSFGILLY430 (Couet et al., 1997) Abl 2G2I (Levinson et al., 2006) a helix 3
Thioredoxin
reductase 1
YHSYFWPLEW411 (Volonte and Galbiati,
2009)*
thioredoxin
reductase 1
3QFA (Fritz-Wolf et al., 2011) b strand 15
Transmembrane Proteins
ALK1 WAFGLVLW406 (Santibanez et al., 2008) ALK1 3MY0  a helix 1.8
Adiponectin
receptor R1
FVPWLYYSF (1),
FFPGKFDIW (2)
(Wang et al., 2012)* none    
Angiotensin YGFLGKKFKRY (Wyse et al., 2003) b1AR 2YO1 (Warne et al., 2011) a helix 
Aquaporin WIFWVGPF219 (Couet et al., 1997) AQP1 1J4N (Sui et al., 2001) a helix 22f
Caveolin FTVTKYWFY (Couet et al., 1997) none    
D1 dopamine FDVFVWFGW (Kong et al., 2007)* none    
Desmogleins FCQKAYAY (Brennan et al., 2011) none    
Endothelin R WPFDHNDFGVF (Couet et al., 1997) none    
Receptor
tyrosine
kinases
WSYGVTVW881 (Couet et al., 1997; EGFR 3LZB (Fidanze et al., 2010) a helix 2
Nystrom et al., 1999; ephrin A3 2QOB (Davis et al., 2008) a helix 1
(Vihanto et al., 2006)* insulin R 1IRK (Hubbard et al., 1994)  
IP3R3 WKINLFMQF
226 (Sundivakkam et al.,
2009)
IP3R1 1XZZ (Bosanac et al., 2005) b strand 32
mAcR WTIGYWLCY (Couet et al., 1997) none    
(Continued on next page)
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Table 1. Continued
Protein Proposed CBM(s) Referenceb
Protein for
Structural
Analysis
PDB
ID
Structure
Reference
Secondary
Structure
Accessible
Surface
Area (%)c
Maxi-K channel
a subunit
YNMLCFGIY1007 (Alioua et al., 2008;
Brainard et al., 2009)*
Maxi-K
cytoplasmic
domain
3MT5 (Yuan et al., 2010) b strand 10
mGluR1a FVTLIFVLY (1),
FNEAKYIAF (2)
(Hong et al., 2009)* none    
MuSK WAYGVVLWEIF795,
FSYGLPQY
(Hezel et al., 2010) MuSK 1LUF (Till et al., 2002) a helix 3
Na/K ATPaseg FCRQLFGGF93 (1),
WWFCAFPY987 (2)
(Cai et al., 2008) Na/K ATPase 3B8E (Morth et al., 2007) a helix/
extended
coil
37f (1),
25f (2)
Neu3 sialidase YTYYIPSW (Wang et al., 2002) none    
nAChR a subunit FSFLTGLVFY234 (Hezel et al., 2010) nAchR 2BG9 (Unwin, 2005) a helix 19f
P-glycoprotein FSMFRYSNW44 (Jodoin et al., 2003)* P-glycoprotein 3G61 (Aller et al., 2009) a helix/
extended
coil
42f
Patched YDFIAAQFKYF (Karpen et al., 2001)* none    
TLR4 FIQSRWCIF715 (Wang et al., 2009) TLR2 1FYW (Xu et al., 2000) a helix/
extended
coil
29
TRPC1 FRTSKYAMF (Sundivakkam et al.,
2009)
none    
b1 adrenergic
receptor
FVFFNWLGY333 (Couet et al., 1997) b1AR 2YO1 (Warne et al., 2011) a helix 31f
Viral and Other Pathogen Proteins
Cholera toxin
subunit A
YGWYRVHF132 (Couet et al., 1997) cholera toxin
subunit A
1S5E (O’Neal et al., 2004) b strand 28
gp41 WNNMTWMQW115 (Hovanessian et al.,
2004; Huang et al.,
2007)
gp41 1QBZ (Yang et al., 1999) a helix 43
M2 channel FFKCIYRRF54 (Zou et al., 2009) M2 channel 2RLF (Schnell and Chou,
2008)
a helix/
extended
coil
64f
Matrix (M) protein FGKSNWGLF (Ravid et al., 2010) none    
Matrix protein FCSAEWPTF45 (Yu et al., 2006) murine
leukemia
virus matrix
protein
1MN8 (Riffel et al., 2002) a helix 29
a-hemolysin WGPYDRDSW187 (Pany et al., 2004) a-hemolysin 3ANZ (Tanaka et al., 2011) extended
coil
41f
aThe CBMs are derived from published studies that show association between caveolin and the identified proteins. These studies suggest that direct
caveolin binding occurs via the indicated CBM, related to the sequence originally proposed by Couet et al., 1997. There were two motifs identified,
UxUxxxxU and UxxxxUxxU, where U is Tyr, Phe, or Trp. Couet et al. further proposed a combined CBM of UxUxxxxUxxU.
bAsterisks (*) indicate that mutagenesis of the CBM was carried out.
cThe accessible surface area is expressed as an average percentage of the total possible surface area of each side chain within the CBM sequence.
Areas were calculated using the program NACCESS (http://www.bioinf.manchester.ac.uk/naccess/).
dNote that the GFP sequence encompasses the cyclized Tyr that forms the chromophore.
eNote that the sequence in PPARa (and also PPARa,b,d) is actually in the reverse sequence orientation to the consensus CBM.
fFor these indicated transmembrane proteins, ‘‘accessible surface area of CBMs’’ will not be an accurate indication of solvent exposure, as the
sequences lie within membrane spanning regions or extracellular domains (Figure S2).
gNote that both sequences fall within the transmembrane domain.
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before adopting a fully folded structure? We cannot rule out
this possibility, but it would almost certainly give rise to14 Developmental Cell 23, July 17, 2012 ª2012 Elsevier Inc.a nonfunctional stable association with caveolin that would not
be subject to the dynamic regulation required during cell
signaling.
Figure 2. Structural Comparison of Several Examples of Putative Caveolin-Interacting Proteins
An enhanced animation of the eNOS structure is provided in Movie S1. Left panels show proteins in ribbon representation, with the CBM indicated in red. Key
aromatic residues of the putative CBMs are highlighted in surface representation. In each case, the key aromatic residues are tightly packed within the protein
hydrophobic core. Middle panels show the same views in surface representation, with CBMs indicated in red. The right panel shows a close-up view of the CBM
and the surrounding environment. Key aromatic residues of the CBMs are shown in red stick representation, and side chains forming direct intramolecular
contacts with these aromatic CBM residues are indicated in gray stick representation. For eNOS, the core heme group is shown in yellow stick representation. All
known structures of putative caveolin-interacting proteins are shown in Figure S2, with references in Table 1. All structure images were prepared using CCP4mg
(McNicholas et al., 2011).
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Table 2. Bioinformatic Analysis of the Abundance of Consensus
CBMs in Mouse and Yeast Proteinsa
Number
of Proteins
Number
Containing
CBM
Overall
Percentage
(%)
Mouse
Full-length proteinsb 33,451 10,076 30
Cytoplasmic sequencesc
Soluble 22,265 5,936 27
Type I transmembrane 1,548 201 13
Type II transmembrane 2,869 335 12
Multipass transmembrane 3,821 739 19
Total 30,503 7,211 24
Noncytoplasmic sequencesc
Soluble 2,948 996 34
Type I transmembrane 1,548 488 32
Type II transmembrane 2,869 608 21
Multipass transmembrane 3,821 773 20
Total 11,186 2,865 26
Yeast
All proteins 6,736 2,883 43
aSequences derived from CYGD database (http://mips.helmholtz-
muenchen.de/genre/proj/yeast/) were scanned for the presence of any
of the two putative CBM sequences, UxUxxxxU and UxxxxUxxU, or
the combined consensus sequence UxUxxxxUxxU (Couet et al., 1997),
where U is either Phe, Trp, or Tyr.4
bThe full set of 51,135 coding sequences was reviewed, and those with
annotated truncations at the N terminus were discarded; topology with
respect to the membrane cannot be accurately determined in this set.
cTopology with respect to the membrane was calculated based on the
presence in sequences of signal peptides and integral membrane
domains using a previously published annotation pipeline (Davis et al.,
2006).
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in Caveolae-Associated Proteins
This analysis raises the question of why somany proteins, partic-
ularly signaling proteins, which have been proposed to interact
with caveolins, possess CBMs. In fact, a systematic bioinfor-
matics analysis of full-length coding sequences from the entire
mouse genome (Carninci et al., 2005) reveals that this motif is
actually present in 30%of all proteins, irrespective of localization
or function (Table 2). The motif is not enriched (and is in fact less
abundant) in cytoplasmic proteins and the cytoplasmic regions
of transmembrane proteins that might conceivably bind caveolin
at the inner leaflet of the plasma membrane. Perhaps most tell-
ingly, the motifs show even greater prevalence in the genome
of Saccharomyces cerevisae, which lacks caveolins altogether.
Thus, it is clear that CBM sequences are not enriched in caveo-
lae-associated molecules, and their widespread abundance
likely reflects a common requirement for hydrophobic aromatic
side chains in protein hydrophobic cores or transmembrane
segments for structural stability and function.
In summary, it is clear from the available structural and
genomic data that the proposedUxUxxxxUxxUCBMsequences
are unlikely to represent a conserved peptide motif for direct
recognition of the caveolin scaffolding domain. Another factor16 Developmental Cell 23, July 17, 2012 ª2012 Elsevier Inc.to consider when assessing the viability of the proposed caveolin
interaction is the position of the putative CBM in the protein,
with respect to the membrane in which caveolin is embedded.
An analogous example is the recognition of tyrosine-containing
motifs by clathrin adaptors, which must be further than 7 amino
acids from the membrane interface to engage with cytoplasmic
proteins (Rohrer et al., 1996). This immediately raises an addi-
tional point regarding interactions with caveolin, because
the maximum distance of the central-most portion of the CSD
from the membrane—assuming a completely and unrealistically
extended structure—is only 30 A˚, corresponding to 10 amino
acids (Figure 1). This will impose severe steric constraints
on any interactions with putative binding partners, which
have been reported to be cytoplasmic proteins, cytoplasmic
domains of transmembrane proteins, or even extracellular
membrane penetrating polypeptides (e.g., gp41, Hovanessian
et al., 2004).
Implications for the Caveolin Signaling Model
Mutations in caveolins or caveolin deficiency can clearly influ-
encemany signaling pathways, as shownboth in vitro and in vivo,
and there is no doubting the role of caveolins in numerous
cellular functions. The signaling proteins listed in Table 1, as
well as many other molecules, can be immunopurified in caveo-
lin-enriched membrane fractions. However, experiments in
which signaling proteins associate with caveolin, as judged by
immunoprecipitation, must be viewed with caution, given the
poor solubility of caveolin-enriched domains (as discussed by
Parton and Simons, 2007), and do not necessarily indicate
a direct protein-protein interaction. A number of studies have
assessed the effect of either deleting or mutating the CBM on
caveolin association and in signaling assays (see Table 1) and
have generally shown a disruption in caveolin interaction and
function. However, the loss of an apparent interaction through
mutation of the proposedCBMwill be highlymisleading if protein
folding, trafficking, or microdomain localization is disrupted, as
seems highly likely given the critical structural roles of the
majority of CBM sequences. Very few reports have addressed
the localization or expression of mutant signaling proteins. The
mutant zebrafish b-catenin protein was found to at least localize
to the nucleus similarly to the wild-type (WT) molecule (Mo et al.,
2010), and the mutant Maxi-K potassium channel a subunit
(Slo1) showed similar sedimentation and oligomeric properties
to the WT protein in sucrose gradients (Alioua et al., 2008). In
contrast, the mutant EphB1 receptor tyrosine kinase was ex-
pressed at lower levels than the WT protein and was not local-
ized to the plasma membrane (Vihanto et al., 2006). Structural
integrity and correct protein folding has not been tested for any
of the mutant proteins, to the best of our knowledge, and should
certainly be a priority in future studies.
The inhibition of signaling processes by cell-permeable
peptides corresponding to the caveolin scaffolding domain
(amino acids 82–101 in caveolin-1) represent an additional line
of evidence supporting the original caveolin scaffolding hypoth-
esis. These studies have demonstrated a striking effect of this
peptide on key signaling pathways involving proteins such as
eNOS, phospholipase D (PLD), and Rac1, both in cultured cells
and in tissues (Bernatchez et al., 2005; Czarny et al., 1999;
Gratton et al., 2003; Kim et al., 1999; Nethe et al., 2010). In animal
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the permeability of the tumor vasculature and delayed tumor
progression, an effect that was reduced in mice lacking the puta-
tive target, eNOS (Gratton et al., 2003). Conversely, a noninhibi-
tory version of this peptide with a single amino acid change
increases basal NO release, an effect lost in tissues lacking
eNOS or caveolin-1 (Bernatchez et al., 2011). However, only
a limited number of studies have attempted to directly test
binding of the CSD peptide to signaling proteins, and in these
cases binding was not investigated in the context of an interac-
tion with putative CBMs (Kim et al., 1999; Nethe et al., 2010).
The analyses presented here should prompt reinvestigation of
the mechanisms involved in inhibition of signaling by these
peptides and, more generally, the effect of loss of caveolin
and/or caveolae on specific signaling pathways. Our findings
certainly do not preclude the regulation of signaling pathways
by caveolins through other mechanisms. These may include
interactions mediated by other regions of caveolin (such as the
interaction with phosphorylated caveolin-1 on tyrosine 14;
Chen et al., 2012; Place et al., 2011) or by completely indepen-
dent mechanisms, including effects on lipid-based organization
of the plasma membrane (Gaus et al., 2006; Hoffmann et al.,
2010) or endocytosis (Cheng et al., 2010; Kirkham et al.,
2005). These effects are also abrogated by mutations in the
caveolin scaffolding domain (Cheng et al., 2010; Hoffmann
et al., 2010).
Taken together, the findings presented here argue against
a role for caveolin binding motifs in driving direct protein recruit-
ment to caveolae. The putative CBM sequence is not enriched in
proteins associated with caveolae, and the motif does not adopt
a common binding structure and is not exposed for caveolin
binding. In most cases, the CBM is part of a critical structural
element, the perturbation of which is likely to lead to protein mis-
folding.We suggest that these considerationsmust be taken into
account in future studies of caveolin interactions. In addition,
previous work implicating caveolin as a scaffold for direct
protein recruitment may need to be reassessed to reveal the
actual mechanisms by which caveolins modulate specific
signaling pathways.
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